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The aim of the present study was to deﬁne the activity and tolerability of a triplet regimen including oxaliplatin 130 mg m
72
(2 h i.v. infusion) and raltitrexed 3.0 mg m
72 (15 min i.v. infusion) given on day 1, followed by levo-folinic acid 250 mg m
72
(2 h i.v. infusion) and 5-ﬂuorouracil 1050 mg m
72 i.v. bolus on day 2, every 2 weeks, in pretreated colorectal cancer patients.
From April 1999 to December 2000, 50 patients were enrolled: 26 were males and 24 females, their median age was 63
(range, 43–79) years; ECOG performance status was 0 in 26 patients, 51 in 24 patients; 26 patients had received previous
adjuvant chemotherapy, 40 patients had been exposed to one or two lines of palliative chemotherapy (including irinotecan in
31 cases); 18 patients were considered chemo-refractory. A total of 288 cycles were administered, with a median number of
6 (range 1–12) courses per patient. A complete response was obtained in three patients, and a partial response in nine
patients, giving a major response rate of 24% (95% conﬁdence interval, 13–38%), while 15 further patients showed a stable
disease, for an overall control of tumour growth in 60% of patients. Three complete responses and three partial responses
were obtained in patients pretreated with irinotecan (response rate, 19%); among refractory patients, three achieved partial
responses (response rate, 13%). After a median follow-up of 18 (range, 10–30) months, 40 patients showed a progression of
disease: the growth modulation index ranged between 0.2 and 2.5: it was 51.33 (showing a signiﬁcant delay of tumour
growth) in 16 (40%) patients. Actuarial median progression-free survival time was 7.6 months, and median survival time was
13.6 months: estimated probability of survival was 55% at 1 year. Main severe toxicity was neutropenia: World Health
Organisation grade 4 affected 32% of patients; non-haematological toxicity was mild: World Health Organisation grade 3
diarrhoea was complained of by 8%, and grade 3 stomatitis by 4% of patients; neurotoxicity (according to Le ￿vi scale) was
scored as grade 3 in 8% of patients. In conclusion, this regimen was manageable and active as salvage treatment of advanced
colorectal cancer patients; it showed incomplete cross-resistance with irinotecan-based treatments, and proved to delay the
progression of disease in a relevant proportion of treated patients.
British Journal of Cancer (2002) 86, 1871–1875. doi:10.1038/sj.bjc.6600414 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: oxaliplatin; ralitrexed; 5-fluorouracil; colon carcinoma; salvage regimen
Until the recent introduction into clinical practice of novel active
agents against colorectal carcinoma, 5-ﬂuorouracil (FU) has been
the mainstay of treatment for this disease. However, only a few
patients show a major response to this drug, with a very modest
effect on long-term survival.
For patients not responding to, or progressing after, FU-based
front-line therapy, both irinotecan (CPT-11) and oxaliplatin (L-
OHP) have been claimed as active in second-line. While CPT-11
has been used as a single agent in this setting, demonstrating to
positively affect the symptom control and the probability of survi-
val of FU-refractory patients (Cunningham et al, 1998; Rougier et
al, 1998), scant experience exists about the activity of L-OHP alone
in second-line (Machover et al, 1996). Indeed, this drug has usually
been used in combination with FU (Bleiberg and de Gramont,
1998; Raymond et al, 1998a), on the grounds of preclinical obser-
vations suggesting that L-OHP has a synergistic antitumour activity
with FU in either FU-sensitive or FU-resistant murine leukaemia
cell cultures or human colonic xenografts transplanted in nude
mice (Fischel et al, 1998; Raymond et al, 1998b; Taron et al,
1999; Plasencia et al, 2001). Recently, in vitro studies on FU-sensi-
tive and FU-resistant HT29 and LoVo cancer cell lines have
demonstrated that the combination of L-OHP+FU induced a
signiﬁcant decrease in thymidylate synthase (TS) expression as
compared to the administration of FU as single agent (Plasencia
et al, 2001).
On the other hand, L-OHP has also been combined with ralti-
trexed (Tomudex
1 (TOM)), a direct and speciﬁc thymidylate
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www.bjcancer.comsynthase inhibitor. Phase I trials with this combination have
already been conducted in Europe, demonstrating that full doses
of both agents (i.e., 130 mg m
72 of L-OHP and 3.0 mg m
72 of
TOM) may be safely combined every 3 weeks. This regimen has
already been assessed in chemonaive as well in previously treated
colorectal cancer patients (Fizazi et al, 2000; Scheithauer et al,
2001a,b).
Interestingly, TOM+FU association has also been shown to exert
additive or synergistic cytotoxic effects in vitro. These ﬁndings may
be explained by the observation that, although the two drugs share
the TS enzyme as the common target, they inhibit it through
different binding sites: polyglutamated TOM binds the folate-bind-
ing site, while FdUMP (the active metabolite of FU) binds the
pyrimidine-binding (i.e., the catalytic) site. Interestingly, in vitro
studies have shown a synergistic activity in HCT-8 colon carcino-
ma cell line with a 24 h TOM exposure followed by a short (4 h)
FU exposure, while a marginal synergy was obtained with the same
sequence but with a prolonged (5-day) FU exposure (Longo et al,
1998). In addition, a phase I study has demonstrated a positive
pharmacokinetic interaction between the two drugs, because a
TOM dosage 52.5 mg m
72 signiﬁcantly increased the Cmax and
the AUC of the following administration of FU (Dragnev et al,
1998).
To elucidate the role of the addition of folinic acid (FA) to this
combination, we have carried out a series of experiments on colon
and head and neck cancer cell lines, exposed to different concentra-
tions of TOM alone, or FU plus levo-FA (LFA), or TOM combined
with FU+LFA, given either simultaneously or with a 24 h interval.
A synergism between TOM and FU+LFA was observed when TOM
preceded FU+LFA in all but one cell line, while the concomitant
exposition reduced the inhibition of cell growth as compared to
TOM alone. The potentiation factor of the addition of LFA to
TOM+FU combination was greater than 1 (ranging from 1.2 to
2) in all cell lines, clearly showing a positive effect of this addition
(Caponigro et al, 2001). These in vitro studies were paralleled by a
clinical trial obtaining a 24% response rate in advanced colorectal
cancer patients with a sequential administration of TOM and
leucovorin-modulated FU given 24 h apart (Comella et al, 2000b).
In consideration of the growing proportion of colorectal cancer
patients that are exposed to combination regimens, including
modulated-FU and either CPT-11 or L-OHP, in the adjuvant
setting as well as in the front-line treatment for the advanced
disease, there is an urgent need to develop alternative regimens
for early relapsing or progressing patients. For this reason, we have
decided to explore the biweekly administration of L-OHP and
TOM plus FU+LFA in pretreated colorectal cancer patients. We
have carried-out a phase I study with this new triplet, concluding
that L-OHP 130 mg m
72, and TOM 3.0 mg m
72 may be given
together on day 1, followed 24 h later by a short infusion of
LFA 250 mg m
72 plus FU 1050 mg m
72 given as i.v. bolus; at
these recommended doses, severe neutropenia was the main acute
toxicity, affecting 31% of patients, while other extra-haematological
adverse events were quite infrequent (Comella et al, 2000a). The
encouraging response rate observed in heavily pretreated patients
prompted us to further assess the activity and tolerability of this
regimen in the present phase II trial.
MATERIALS AND METHODS
Patient selection
Patients affected by histologically proven colorectal carcinoma were
eligible for this study. At least one measurable indicator lesion was
required. All patients must have been pretreated with FU-based
regimen, either as adjuvant or palliative chemotherapy, and
previous treatment should have been discontinued for at least 4
weeks. In addition, a good bone marrow reserve was required, with
an absolute neutrophil count (ANC) 51500 per mm
3, a platelet
(PLT) count 5100000 per mm
3, and haemoglobin level
59.5 g dl
71; in absence of liver metastases, bilirubin serum level
should have been 41.5 6 upper normal limit (UNL), and ASAT
and ALAT 42.5 6 UNL. Exclusion criteria were: presence of brain
metastases; poor performance status (53 of the ECOG scale); a life
expectancy 512 weeks; uncontrolled metabolic disorders or active
infections. Written informed consent was required from each
patient before the admission to this trial, which was approved by
the Independent Ethical Committee of the National Tumour Insti-
tute of Naples.
Treatment
Patients were submitted to a biweekly regimen consisting of L-
OHP 130 mg m
72 diluted in 500 ml of 5% DW solution given
i.v. over 2 h, followed by TOM 3.0 mg m
72 as short (15 min)
i.v. infusion on day 1; on the day 2, LFA 250 mg m
72 was admi-
nistered as 2 h i.v. infusion, at the end of which FU 1050 mg m
72
was given as i.v. bolus. Cycles were repeated every 2 weeks, in
the presence of ANC count 51500 per mm
3, PLT count
5100000 per mm
3, and provided that any non-haematological
toxicity had recovered to a grade 41. Otherwise, a 1- or 2-week
delay was allowed. If toxicity persisted at that time, patients went
off study. In the presence of grade 4 haematological toxicity, or
in the presence of grade 53 non-haematological toxicity, the
subsequent cycles were administered, after recovery, with a 25%
dose reduction of all cytotoxic drugs. L-OHP dosage was reduced
by 25% only in presence of grade 3 toxicity (persistence of periph-
eral toxicity at the time of recycling).
Evaluation of toxicity
For the assessment of acute toxicity, blood cell counts were
performed weekly, and twice a week in the case of grade 4 toxicity.
Biochemistry was performed before each cycle. History and neuro-
logical examination, to detect any sign of neurotoxicity, was
performed at initial treatment and at every cycle thereafter. The
acute toxicity was graded according to World Health Organisation
(WHO) toxicity criteria (Miller et al, 1981). Neurotoxicity was
scored according to the Le ￿vi scale (Le ￿vi et al, 1992).
Evaluation of response
At study entry, all patients were submitted to routine chemistry,
blood cell count, CEA and CA 19.9 serum level determinations,
chest X-ray and abdominal ultrasound scan. Indicator lesions were
measured with CT or MNR imaging. Endoluminal recurrent or
unresected disease was evaluated with ﬁberoptic endoscopy.
WHO criteria were adopted for the evaluation of response (Miller
et al, 1981). To classify the type of response, all tests which were
abnormal at baseline were repeated after every four cycles of treat-
ment.
Statistical consideration and sample size
We used the statistical design of Gehan (1961) for this phase II
study: assuming for the experimental regimen a 15% activity rate,
a minimum of 14 patients had to be treated. In case of no major
response, the accrual could be stopped, and this hypothesis rejected
with a 95% conﬁdence. Otherwise, a number of additional patients,
according to the number of responses observed among the ﬁrst 14,
had to be enrolled to estimate the true activity of this regimen.
Time to tumour progression before study entry (TTP1) was
recorded for each patient. Time to further tumour progression
(TTP2) was evaluated from the date of study entry to the date of
documented progressive disease. The TTP2/TTP1 ratio was calcu-
lated to obtain the growth modulation index (GMI) (Von Hoff,
1998; Bonetti et al, 2001). Probability of progression-free and over-
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accrual to the date of progression, death, or last follow-up, respec-
tively (Kaplan and Meier, 1958).
RESULTS
Patient characteristics
From April 1999 to December 2000, a total of 50 eligible patients
were enrolled into this study from six institutions. The main char-
acteristics of this case series are listed in Table 1. The majority of
patients had a good performance status. However, it should be
noted that most of them (80%) had been exposed to chemotherapy
for palliative intent (including irinotecan in 62% of them), and
18% had received more than one line of chemotherapy. On the
basis of the previous exposure to chemotherapy, 18 patients
(36%) were deﬁned as chemo-sensitive, because they had showed
a relapse of disease after 6 months from the end of adjuvant
chemotherapy, and/or had achieved a major response with previous
palliative chemotherapy, and/or the TTP1 was longer than 6
months; 14 patients (28%) were considered chemo-resistant,
because they had a recurrence within 6 months from the disconti-
nuation of adjuvant chemotherapy, and/or the TTP1 was shorter
than 6 months; while 18 patients (36%) were deﬁned as chemo-
refractory, because of recurrence or progression of disease during
adjuvant or palliative chemotherapy. Sites of disease were typical
for these patients, with 74% of them having liver involvement.
Twenty-one (42%) patients had only one site of disease, while 29
(58%) had two or more sites.
Activity
A total of 288 cycles were delivered, with a median number of six
(range, 1–12) cycles per patient. Forty (80%) patients received at
least four courses, while eight cycles were delivered to 21 (42%)
patients. At the time of this report, we had obtained three complete
responses (CRs) and nine partial responses (PRs), for an overall
response rate (RR) of 24% (95% conﬁdence interval, 13–38%),
according to intent-to-treat analysis. Three further patients showed
a shrinkage of tumour burden that did not qualify for a major
response, while 15 patients showed stable disease; tumour progres-
sion was clearly demonstrated in 15 patients, while ﬁve patients
were not assessed (Table 2). The complete disappearance of disease
was achieved in three patients, who had a single lesion in the liver
in two patients and lung in one patient. Two of them eventually
recurred after 5.5 and 6.4 months, while the third one is still in
CR at 12.4 months of follow-up. All but four responses were
reached within 3 months from initial treatment, and lasted a
median of 8 (range, 4.1–16.4) months. It is worth noting that
three CRs and three PRs were obtained in patients pretreated with
irinotecan (for a 19% RR in this subset of patients), while three
PRs (RR=17%) were achieved among outright refractory patients.
Extent of disease affected the probability of response, because a
major tumour shrinkage was obtained in seven of 21 (33%)
patients with one site of disease, compared to ﬁve out of 29
(17%) patients with two or more sites.
As of October 2001, with a median follow-up of 18 (range, 10–
30) months, 40 (80%) patients had showed a further tumour
progression. The GMI for these patients ranged between 0.2 and
2.5. Sixteen (40%) patients had a GMI 51.33, proving that the
regimen produced a signiﬁcant delay of tumour growth. Interest-
ingly, such ﬁndings appear unrelated to previous chemo-
sensitivity. Indeed, it was observed in eight of 14 (57%) refractory
patients, as compared to eight of 24 (33%) remaining patients.
Overall median progression-free survival was 7.6 months. Eleven
patients received additional treatment (capecitabine, eight patients;
irinotecan, two patients; surgical resection of residual liver deposit,
one patient). Thirty-three (66%) patients have died, all but one
because of progressive disease. A 79-year-old patient died after
two cycles because of heart failure, which might have been related
to the administered chemotherapy. Overall median survival time
was 13.6 months, and actuarial 1- and 2-year probabilities of survi-
val were 55% and 9%, respectively.
Safety
Two patients were not evaluable for toxicity, because of early
discontinuation of treatment for refusal and lack of information
after the ﬁrst cycle. Apart from the previously mentioned early
death, no toxic deaths were reported. Neutropenia was the main
haematological adverse event: it was recorded during treatment
in 81% of patients, and reached WHO grade 4 in 31%. Thrombo-
cytopenia of any grade was noted in 40% of patients, but it never
required platelet transfusions. Anaemia was rarely reported, and
only two patients required a packed red cell transfusion (Table
3). Neutropenic fever or infection occurred in two patients. As
for non-haematological toxicity, gastrointestinal disturbance and
peripheral neuropathy were frequently encountered. Vomiting
and diarrhoea affected 56% and 48% of patients, but they reached
grade 3 (no grade 4 was recorded) in 9% and 8%, respectively.
Stomatitis affected about one third of patients, but it was grade
3 in 4% of them. Oxaliplatin-induced neurotoxicity was com-
plained of by many patients, but it usually recovered before recy-
cling without dose reduction. Ten (21%) patients complained of
some fatigue attributable to treatment, which was severe in four
cases. A mild and transient liver enzymes derangement was noted
in 13% of patients. Due to occasional neutropenia, a reduction
of all cytotoxic drugs was required in many patients; as a conse-
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Table 1 Patient characteristics
Characteristics No. points %
Total population 50 100
Males 26 52
Females 24 48
Median age (years) 63
range 43–79
PS (ECOG) 0 26 52
12 2 4 4
22 4
Site of primary
Colon or recto-sigmoid colon 27 54
Rectum 23 46
Previous 5FU adjuvant treatment 26 52
Previous palliative treatment 40 80
including topoisomerase I inhibitors 31 62
41 line of palliative treatment 9 18
Chemo-sensitive patients 18 36
Chemo-resistant patients 14 28
Chemo-refractory patients 18 36
Presence of symptoms 19 38
Weight loss 12 24
No. sites 1 21 42
22 2 4 4
537 1 4
Liver 37 74
Lung 20 40
Peritoneum 11 22
Pelvic relapse 10 20
Nodal 7 14
CEA 553 7 8 6
mean value (range) 621 (1–13 500)
CA 19.9 535 30 70
mean value (range) 1038 (1–19 191)
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(12), 1871–1875quence, the mean actually delivered L-OHP dose intensity over
eight cycles was 41 mg m
72 per week, which represented a 63%
relative dose intensity (RDI). The corresponding value for TOM
was 1.0 mg m
72 per week (67% RDI), and for FU was
336 mg m
72 per week (64% RDI).
DISCUSSION
Despite the notable progress achieved in the management of
advanced colorectal carcinoma, the prognosis of patients remains
extremely poor. Also after the introduction into clinical practice
of combination regimens, in which leucovorin-modulated FU has
been associated with other active drugs such as CPT-11 or L-
OHP, only a few-months delay of disease progression is gained
in comparison with standard modulated-FU regimens. Further-
more, in the near future the standard adjuvant treatment of
surgically resected node-positive colorectal cancer patients will
likely entail a CPT-11-including regimen. Therefore, there is an
urgent need for evaluating novel non-cross-resistant regimens for
patients already exposed to CPT-11 plus modulated FU.
The regimen we have assessed in this study yielded a major
response in 24% of patients, while 36% obtained at least a stabili-
sation of disease, so that tumour control was obtained in 60% of
the whole series. It is also noteworthy that three CRs were achieved
in this study. These CRs, although obtained in single metastatic
deposits, were observed after previous exposure to topoisome-
rase-I inhibitors, suggesting a lack of cross-resistance between
this class of drugs and oxaliplatin-based regimen. On the contrary,
a weaker activity (13%) was seen among outright refractory
patients. However, despite the low proportion of major responses
reported among these patients, a signiﬁcant improvement in
tumour progression, as reﬂected by the GMI, was obtained in
57% of them. In addition, the progression-free and overall survival
time of this heavily pretreated case series compared favourably with
those reported with single-agent irinotecan after FU failure
(Cunningham et al, 1998; Rougier et al, 1998). Although a formal
assessment of quality of life was not performed in our study, it is
likely that the delay of tumour growth obtained in many patients
was paralleled by a delay of worsening of symptoms. Acute toxicity
of this regimen was substantial but manageable. Indeed, despite the
high frequency of severe neutropenia, neutropenic fever or infec-
tion rarely occurred, while severe non-haematological adverse
events were seldom observed. However, due to occasional neutro-
penia, we were frequently forced to reduce the planned dosages
during treatment, so impairing the ideal dose intensity of this
treatment. Therefore, our regimen could probably be easily admi-
nistered with a 3-weekly schedule; otherwise, using a biweekly
schedule in order to keep a dose-dense treatment, a substantial
reduction of all cytotoxic drugs seems advisable. Anyway, the
short-lasting infusion of all cytotoxic drugs over a few hours in
two separate days made this regimen convenient also for an out-
patient management, because the placement of an indwelling
central venous catheter and/or the use of infusional devices were
not required.
Recently, a doublet regimen of L-OHP plus TOM given on the
same day at full doses (130 and 3.0 mg m
72, respectively) every 3
weeks has been tested in a small series of advanced colorectal
cancer patients (Scheithauer et al, 2001b). All patients had
previously received one palliative FU-based regimen, which
included irinotecan in 11 of them. Twelve out of 36 (33%) patients
achieved a major response. However, only one of 10 truly refrac-
tory patients (progressing on ﬁrst-line therapy) responded to this
salvage regimen. Median progression-free and overall survival were
6.5 and 411 months, respectively. Grades 3 or 4 neutropenia
affected 23% of patients. Mean dose intensity was 40.34 mg m
72
per week for L-OHP, and 0.986 mg m
72 per week for TOM.
On the other hand, the addition of L-OHP in patients progres-
sing during a FU-based regimen has been recently addressed, with
particular emphasis on the GMI measured in each patient. Indeed,
while only three of 34 (9%) patients obtained a major response
after the addition of L-OHP to FU, 16 (43%) of them showed a
GMI 51.33. The median TTP1 was 13 weeks, and the median
TTP2 was 31 weeks. The median overall survival time from the
start of second-line chemotherapy was 12.8 months. This observa-
tion corroborated the hypothesis that a decrease of tumour growth,
rather than a signiﬁcant shrinkage of tumour mass, may positively
affect the survival of patients.
The results obtained in our study in terms of activity and/or
control of tumour progression are in agreement with those reports.
As for toxicity, the shorter recycling we have adopted may explain
the greater incidence of neutropenia. However, the actually deliv-
ered dose intensity in our series was superimposable to that
reported by the above mentioned study of Scheithauer et al
(2001b) for L-OHP and TOM, despite the addition in our regimen
of modulated FU. Of course, one could wonder whether this addi-
tion was needed, because of the previous exposure to FU in all
patients, and because of the questionable role of FU given together
with TOM.
As for the ﬁrst issue, we would remember that recent in vitro
studies have demonstrated an increased TS expression shortly after
the L-OHP exposure, while the sequential administration of L-
OHP before FU induced a signiﬁcant decrease of TS expression,
both in sensitive and resistant cell lines (Plasencia et al, 2000,
2001). Since a common cause of FU resistance is the over-expres-
sion of TS, it sounds wise to combine L-OHP and FU also in
patients previously exposed to FU.
As for TOM and FU combination, taking into account the
different binding sites, and the potentially additive or synergic inhi-
bitory effects on TS of these two drugs, namely when given 24 h
apart, we devised to assess a new regimen, in which L-OHP plus
TOM administration preceded by 24 h the LFA plus FU exposure.
Finally, we should remember that, as a consequence of the
increasing utilisation of CPT-11 combined with modulated-FU in
the adjuvant setting as well as in front-line treatment for the
advanced disease, in the next few years the medical oncologists will
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Table 2 Activity reported among treated patients
Responses No. %
Complete 3 6
Partial 9 18
Minor 3 6
Stable 15 30
Progression 15 30
Not assessed 5 10
Total patients 50 100
Table 3 Acute toxicity (as percentage of 48 assessable patients)
WHO grade
Toxicity 1234 T o t a l
Neutropenia 10 19 21 31 81
Anaemia 19 10 4 0 23
Thrombocytopenia 15 15 10 0 40
Vomiting 36 11 9 0 56
Diarrhoea 23 17 8 0 48
Stomatitis 17 11 4 0 32
Alopecia 4 11 6 0 21
Neurologic 45 8 8 0 61
Hepatic 13 0 0 0 13
Infection 0110 2
Asthenia 7780 2 2
Cutaneous 0020 2
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patients. From the present study, we conclude that our regimen
represents a suitable option for some of these patients, provided
that acute toxicity might be reduced by employing decreased doses
or a 3-weekly schedule. However, outright refractory patients prob-
ably need a different approach with newer drugs.
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